Publication: Management of chronic prostatitis/chronic pelvic pain syndrome: A systematic review and network meta-analysis
Issued Date
2011-01-05
Resource Type
ISSN
15383598
00987484
00987484
Other identifier(s)
2-s2.0-78650889471
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
JAMA - Journal of the American Medical Association. Vol.305, No.1 (2011), 78-86
Suggested Citation
Thunyarat Anothaisintawee, John Attia, J. Curtis Nickel, Sangsuree Thammakraisorn, Pawin Numthavaj, Mark McEvoy, Ammarin Thakkinstian Management of chronic prostatitis/chronic pelvic pain syndrome: A systematic review and network meta-analysis. JAMA - Journal of the American Medical Association. Vol.305, No.1 (2011), 78-86. doi:10.1001/jama.2010.1913 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/12703
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Management of chronic prostatitis/chronic pelvic pain syndrome: A systematic review and network meta-analysis
Abstract
Context: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is common, but trial evidence is conflicting and therapeutic options are controversial. Objective: To conduct a systematic review and network meta-analysis comparing mean symptom scores and treatment response among α-blockers, antibiotics, anti-inflammatory drugs, other active drugs (phytotherapy, glycosaminoglycans, finasteride, and neuromodulators), and placebo. Data Sources: We searched ME DLINE from 1949 and EMBASE from 1974 to November 16, 2010, using the PubMed and Ovid search engines. Study Selection: Randomized controlled trials comparing drug treatments in CP/CPPS patients. Data Extraction: Two reviewers independently extracted mean symptom scores, quality-of-life measures, and response to treatment between treatment groups. Standardized mean difference and random-effects methods were applied for pooling continuous and dichotomous outcomes, respectively. A longitudinal mixed regression model was used for network meta-analysis to indirectly compare treatment effects. Data Synthesis: Twenty-three of 262 studies identified were eligible. Compared with placebo, α-blockers were associated with significant improvement in symptoms with standardized mean differences in total symptom, pain, voiding, and quality-of-life scores of -1.7 (95% confidence interval [CI], -2.8 to -0.6), -1.1 (95% CI, -1.8 to -0.3), -1.4 (95% CI, -2.3 to -0.5), and -1.0 (95% CI, -1.8 to -0.2), respectively. Patients receiving α-blockers or anti-inflammatory medications had a higher chance of favorable response compared with placebo, with pooled RRs of 1.6 (95% CI, 1.1-2.3) and 1.8 (95% CI, 1.2-2.6), respectively. Contour-enhanced funnel plots suggested the presence of publication bias for smaller studies of α-blocker therapies. The network meta-analysis suggested benefits of antibiotics in decreasing total symptom scores (-9.8; 95% CI, -15.1 to -4.6), pain scores (-4.4; 95% CI, -7.0 to -1.9), voiding scores (-2.8; 95% CI, -4.1 to -1.6), and quality-of-life scores (-1.9; 95% CI, -3.6 to -0.2) compared with placebo. Combining α-blockers and antibiotics yielded the greatest benefits compared with placebo, with corresponding decreases of -13.8 (95% CI, -17.5 to -10.2) for total symptom scores, -5.7 (95% CI, -7.8 to -3.6) for pain scores, -3.7 (95% CI, -5.2 to -2.1) for voiding, and -2.8 (95% CI, -4.7 to -0.9) for quality-of-life scores. Conclusions: α-Blockers, antibiotics, and combinations of these therapies appear to achieve the greatest improvement in clinical symptom scores compared with placebo. Antiinflammatory therapies have a lesser but measurable benefit on selected outcomes. However, beneficial effects of α-blockers may be overestimated because of publication bias. ©2011 American Medical Association. All rights reserved.